0.95Open0.95Pre Close0 Volume541 Open Interest260.00Strike Price0.00Turnover48.88%IV11.92%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.95Extrinsic Value100Contract SizeAmericanOptions Type0.1056Delta0.0094Gamma245.42Leverage Ratio-0.1667Theta0.0069Rho25.92Eff Leverage0.0726Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet